Administrative Supplements to Support Cancer Disparity Tender
Notice for Administrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional) in USA. The reference ID of the tender is 63757571 and it is closing on 23 Jan 2025.
Tender Details
- Country: USA
- Summary: Administrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional)
- UST Ref No: 63757571
- Deadline: 23 Jan 2025
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: Refer Document
- Notice Type: Tender
- Document Ref. No.: PAR-22-114
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Tender are invited for Administrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional)
CFDA Number : 93.393 -- Cancer Cause and Prevention Research93.394 -- Cancer Detection and Diagnosis Research93.395 -- Cancer Treatment Research93.396 -- Cancer Biology Research93.397 -- Cancer Centers Support Grants93.398 -- Cancer Research Manpower93.399 -- Cancer Control
Cost Sharing or Matching Requirement : No
Closing Date for Applications: Jan 23, 2025
Posted Date : Feb 25, 2022
Description: The purpose of this trans-NCI Funding Opportunity Announcement (FOA) is to promote new cancer disparities research among investigators who do not normally conduct it and to encourage the partnership of experienced cancer research investigators with cancer disparities-focused researchers. This FOA is intended to accelerate and strengthen multi-disciplinary cancer disparities research in wide ranging areas. Cancer disparities research includes, but is not limited to basic, translational, behavioral, observational, interventional, environmental and population research studies that address the adverse differences in cancer incidence, prevalence, mortality, survivorship, burden and/or response to treatment in racial/ethnic minorities and/or underserved population groups. Proposed collaborations should focus on achieving research objectives that by necessity rely on diverse and complementary expertise, technic... - Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINAdministrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional) - USA Tender
The NATIONAL INSTITUTES OF HEALTH, a Government sector organization in USA, has announced a new tender for Administrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional). This tender is published on USARFP under UST Ref No: 63757571 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-01-23.
The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
Fresh and verified Tenders from USA. Find, search and filter Tenders/Call for bids/RFIs/RFPs/RFQs/Auctions published by the government, public sector undertakings (PSUs) and private entities.
- 1,000+ Tenders
- Verified Tenders Only
- New Tenders Every Day
- Tenders Result Data
- Archive & Historical Tenders Access
- Consultants for RFI/RFP/RFQ
- Tender Notifications & Alerts
- Search, Sort, and Filter Tenders
- Bidding Assistance & Consulting
- Customer Support
- Publish your Tenders
- Export data to Excel
- API for Tender Data
- Tender Documents
Fill out the form below and you will receive a call from us within 24 hours.
Get FREE SAMPLE TENDERS from USA in your email inbox.
Copyright © 2014-2026 USARFP.com. All Rights Reserved.


